INHIBITORS OF BRUTON'S TYROSINE KINASE

• US 20130018032A1
• Filed: 07/13/2012
• Published: 01/17/2013
• Est. Priority Date: 07/13/2011
• Status: Active Grant

• Current Assignee: Pharmacyclics LLC (Abbvie Incorporated)
• Original Assignee: Pharmacyclics Incorporated (Abbvie Incorporated)
• Inventors: Loury, David J., Mody, Tarak D., Wang, Longcheng, CHEN, Wei
• Granted Patent: US 9,138,436 B2
• Time in Patent Office: Days
• US Class Current: 514/210.18
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07D 473/34 attached in position 6, e.g. adenine
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

Claims

1. A compound having the structure of Formula (I):

2. A compound having the structure of Formula (II):

3. A compound having the structure of Formula (III):

4. A compound having the structure of Formula (IV):

5. A compound having the structure of Formula (V):

6. A compound having the structure of Formula (VI):

16. A pharmaceutical composition comprising a compound of claim 6, or a pharmaceutically acceptable salt, solvate, N-oxide, or prodrug thereof;

and a pharmaceutically acceptable excipient, binder or carrier.

17. A method for treating an autoimmune disease comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a compound of claim 6.

18. A method for treating a heteroimmune condition or disease comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a compound of claim 6.

19. A method for treating an inflammatory disease comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a compound of claim 6.

20. A method for treating a cancer comprising comprising administering to a subject in need thereof a composition containing a therapeutically effective amount of a compound of claim 6.

7. A compound having the structure of Formula (VIA)

8. A compound having the structure of Formula (VII)

9. A compound having the structure of Formula (VIII)

10. A compound having the structure of Formula (IX)

11. A compound having the structure of Formula (X)

12. A compound selected from:

13. A compound selected from:

14. A compound selected from:

15. A compound selected from: